Shukra Pharmaceuticals Ltd. has received a Letter of Intent (LoI) from the Yamuna Expressway Industrial Development Authority (YEIDA) for the allocation of 10 acres of land at the Medical Device Park in Sector 28, Greater Noida. The company plans to invest nearly ₹600 crore to establish a state-of-the-art healthcare manufacturing facility.
The upcoming facility will focus on manufacturing advanced surgical robotic systems and Boron Neutron Capture Therapy (BNCT) technology, an emerging cancer treatment used for complex and difficult-to-treat tumours. The project is expected to create over 900 direct jobs and approximately 2,000 indirect employment opportunities, providing a significant boost to the regional med-tech ecosystem and strengthening India’s capabilities in high-end medical technologies.
The initiative aligns with the government’s objective of positioning India as a global centre for healthcare innovation and medical device manufacturing.
Separately, Shukra Pharmaceuticals has entered into a Memorandum of Understanding (MoU) with US-based Borns Medical Robotics Inc. to bring advanced surgical robotics technology to India. The agreement was formalised at an event in New Delhi and will facilitate the introduction of the Veer Surgical Robot, an AI-enabled surgical platform aimed at improving precision, safety, and consistency in surgical procedures, while expanding access to advanced care.
Dr Minakshi Late, CEO and Global Head of Shukra Ltd., said the partnership marks an important step towards strengthening India’s self-reliance in healthcare technology. She noted that the joint venture supports the vision of Atmanirbhar Bharat and aims to make advanced surgical solutions affordable and accessible, particularly in underserved regions.
Dr Alexander T. Teichmann, Chief Medical Officer of Borns Medical Robotics Inc., said the collaboration combines Borns’ expertise in AI-driven robotics with Shukra’s manufacturing capabilities and market presence. He added that the partnership seeks to standardise surgical outcomes, empower surgeons, and build scalable healthcare infrastructure across India and Asia.
Dakshesh Shah, Chairman and Managing Director of Shukra Pharmaceuticals Ltd., emphasised the company’s focus on expanding access to advanced healthcare technologies beyond metropolitan centres. He said the partnership would help ensure that robotic surgery becomes available to a wider patient population across the country.
Dr Vivek Bindal, Director and Head of Max Institute of Robotic Surgery, Patparganj, said next-generation robotic platforms such as Veer have the potential to transform surgical care in India. He highlighted features including single-port surgery, AI-enabled safety systems, and advanced micro-instruments, which could improve access to minimally invasive procedures while reducing overall treatment costs.
The company said the collaboration will also focus on developing end-to-end manufacturing and distribution capabilities in India, along with surgeon training programmes and the creation of supporting clinical infrastructure, to build a scalable and sustainable robotic surgery ecosystem in the country.